+234 1 270 1652



Price	N 149.00
52-week range	₩136.10 - 221.50
Market Cap. (N 'bn)	2,539.96
1-month Avg. Vol	4,956,791
Curr. PE	6.6x

240 210 180 150 120 Oct-18 Feb-19 Jun-19 Oct-19

Analyst

Janet Ogunkoya Janet.ogunkoya@arm.com.ng

Dangote Cement Plc. (DANGCEM.NL)

Initial View

Growth in top line smeared by promo expenses and FX loss

- DANGCEM released Q3 19 results today, with reported EPS declining 22% YoY to №2.06, to lag our estimate of №2.91. While group revenue came largely in line with our expectation, the deviation stemmed from higher than expected FX translation loss on subsidiary obligations worth of №7 billion. Beyond the impact of FX loss on the bottom line, operating performance was weak over the quarter as a combination of faster increase in production cost (reflecting higher energy prices, similar to CCNN) and higher sales and distribution expenses, led to contraction in both gross and EBIT margins by 130 bps and 390 bps YoY to 54% and 29% respectively. Intuitively, group revenue (+4.5% higher YoY) remained resilient as stronger growth in Nigeria (9% YoY) more than offset the decline in Pan African sales (3% YoY). Cumulatively, 9M 19 EPS is down 2.5% YoY to №9.06.
- Interestingly, the management of DANGCEM announced a share buy-back and reverse share split prior to the release of its Q3 report today. While further details have not been announced, we believe the share action would support valuation and a possible rerating of the stock in the near term. On our numbers, we run a scenario of possible impact the split could have on our forecast EPS, DPS and FVE using the potential impact of a 5%, 10% and 15% reduction in current outstanding shares.

Table 1: Scenario analysis of share buy-back

	Current	5%	10%	15%	
Nos of shares ('Mn)	17,041	16,188	15,336	14,484	
EPS	13.96	14.69	15.51	16.42	
DPS	11.09	11.68	12.33	13.05	
FVE	240.87	253.55	267.63	283.38	
BVPS	50.27	52.91	55.85	59.14	
P/E	10.68	10.14	9.61	9.08	
P/B	2.96	2.82	2.67	2.52	
Source: ARM Research, Company filling					

• The growth in Nigeria revenue stemmed largely from increase in volumes (+9% YoY to 3.2MT) while price was nearly flat at №43,138 (+0.35% YoY, -1.4% QoQ). To mention, the growth in Nigeria volume was stunted by the boarder closure which, according to management, drove exports' contribution to sales from ~5% to 0. Meanwhile, weak demand and increased competition in South Africa and Ghana led to

lower volume (-0.16% YoY) and prices (-3.2% YoY) which drove Pan-Africa revenue lower during the quarter by 3.3% YoY to \$\frac{\text{N}}{7}3\$ billion. *Meanwhile*, *there was a faster increase in COGS by 7.5% YoY* which led to a contraction in gross margin by 130 bps YoY to 54.3%. COGS per tonne was up 2% YoY to \$\frac{\text{N}}{16},147/ton, owing to pressure from higher energy cost (+10% YoY to \$\frac{\text{N}}{5},331/ton).

- As stated earlier, DANGCEM ramped up its promotional activities in Nigeria during the quarter in a bid to salvage market share, which was evident in the increased volumes as well as slight improvement in market share (from 62.6% over H1 19 to 63.2% in 9M 19). As a result, S&D per ton rose 13% YoY to ¥7,339. This put some pressure on EBIT margin which contracted 390 bps YoY to 29%, while EBIT dipped 8% YoY to ¥61 billion.
- The spike in FX loss (N7 billion) in the quarter was due to depreciation of Pan-African currencies, especially in Ghana and Sierra Leonne, as against N5 billion FX gain in Q3 18. As a result, net finance cost spiked 4.2x of Q3 18 to N18.8 billion. This led to a plunge in PBT by 32% YoY to N42 billion, while the blow softened on PAT (-22% YoY to N35 billion), owing to a lower effective tax rate (-10 bps YoY to 27%). This is due to the pioneer tax credit 2-year extensions on the Obajana and Ibese lines which was received approval earlier this year.
- Overall, we view the growth in revenue as positive, while the higher S&D and FX loss smeared the performance in bottom line. Our FVE of \$\frac{\textbf{N}}{2}40.87\$ holds a potential upside of 61% from current price and translates to a BUY rating. DANGCEM has a forward P/E of 10.7x which is a discount to MENA peer average of 21.9x.

Summary of Results

Income statement – (₦' million)	Q3 19	Q3 18	YoY growth	QoQ growth	9M 19	9M 18	YoY growth
Volume ('000 tons)	5,678	5,407	5%	-4%	17,960	17,782	1%
Price/ton (N)	37,348	37,516	-0.4%	-2%	37,850	38,558	-2%
Revenue	212,061	202,851	5%	-7%	679,791	685,290	-1%
Cost of sales	96,843	90,087	7%	3%	290,015	287,682	1%
Gross profit	115,218	112,764	2%	-14%	389,776	397,608	-2%
OPEX	55,052	48,401	14%	5%	160,342	135,264	19%
Operating profit	60,986	66,343	-8%	-26%	231,482	266,860	-13%
Net interest expense	20,167	11,550	75%	155%	-33,802	-19,496	73%
PBT	42,192	61,826	-32%	-45%	197,680	247,364	-20%
PAT	35,110	45,113	-22%	-40%	154,350	158,277	-2%
EPS	2.06	2.65	-22%	-40%	9.06	9.29	-2%

Key Ratios	Q3 19	Q3 18	Change(pps)	9M 19	9M 18	Change(pps)
Gross margin	54.33%	55.59%	-1.26%	57.34%	58.02%	-0.68%
EBIT margin	28.76%	32.71%	-3.95%	34.05%	38.94%	-4.89%
PBT margin	19.90%	30.48%	-10.58%	29.08%	36.10%	-7.02%
PAT margin	16.56%	22.24%	-5.68%	22.71%	23.10%	-0.39%
Effective tax rate	16.79%	27.03%	-10.25%	21.92%	36.01%	-14.10%

Source: ARM Research *unless otherwise stated

ARM ratings and recommendations

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for ratings subject to target price deviation is outlined below:

TOP 20		NON-TOP 20	
Rating	Deviation	Rating	Deviation
STRONG BUY	>20%	BUY	>20%
OVERWEIGHT	10% — 20 %	NEUTRAL	5% — 20 %
NEUTRAL	0% — 10 %	SELL	<5%
UNDERWEIGHT	-5% — 0%		
SELL	<-5%		

RECOMMENDATION KEY			
Rating	Recommendation		
BUY	Accumulate security to a substantial extent constrained only by portfolio diversification considerations		
OVERWEIGHT	Accumulate security to an extent moderated by cognizance of its benchmark weight		
NEUTRAL	Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—subject to reas portfolio constraints		
UNDERWEIGHT	Minimize exposure to security taking cognizance of its index weighting		
SELL	Sell-off security completely from portfolio		

Copyright © 2019 ARM Securities Limited ("ARMS").

All rights reserved. Unauthorised use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARMS and its analysts believe to be reliable. Neither ARMS nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARMS, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.